Page last updated: 2024-12-08
phrenosin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
phrenosin: galactoside from brain substance; yields galactose, sphingosine, phrenosinic acid on hydrolysis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1-(beta-D-galactosyl)-N-[(2R)-2-hydroxylignoceroyl]sphingosine : A D-galactosyl-N-acylsphingosine in which the ceramide N-acyl group is specified as (R)-2-hydroxylignoceroyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71768128 |
| CHEBI ID | 75966 |
| MeSH ID | M0063545 |
Synonyms (15)
| Synonym |
|---|
| phrenosin |
| CHEBI:75966 |
| (2r)-n-[(2s,3r,4e)-1-(beta-d-galactopyranosyloxy)-3-hydroxyoctadec-4-en-2-yl]-2-hydroxytetracosanamide |
| 2-hydroxytetracosanoylgalactosylceramide |
| 1-(beta-d-galactosyl)-n-[(2r)-2-hydroxylignoceroyl]sphingosine |
| 1-(d-galactosyl)-n-(2r)-2-hydroxy-tetracosanoylsphingosine |
| 2-oh-24:0-galc |
| unii-xrv46r3bsq |
| tetracosanamide, n-((1s,2r,3e)-1-((beta-d-galactopyranosyloxy)methyl)-2-hydroxy-3-heptadecen-1-yl)-2-hydroxy-, (2r)- |
| tetracosanamide, n-((1s,2r,3e)-1-((.beta.-d-galactopyranosyloxy)methyl)-2-hydroxy-3-heptadecen-1-yl)-2-hydroxy-, (2r)- |
| phrenosine (ox brain) |
| 586-02-7 |
| phrenosin [mi] |
| XRV46R3BSQ , |
| Q27145663 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| N-acyl-beta-D-galactosylsphingosine | An N-acyl-D-galactosylsphingosine in which the anomeric configuration of the galactosyl residue is beta; sphingosine substituted at the O-1 position by a beta-D-galactosyl group and at the N-2 position by an acyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||